Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. The company offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne. Botanix Pharmaceuticals Limited is based in Perth, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-8-94820580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.67 million
Profitability
Miscellaneous
Employees10
Next Earnings DateN/A
OptionableNot Optionable
Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions
What is Botanix Pharmaceuticals' stock symbol?
Botanix Pharmaceuticals trades on the ASX under the ticker symbol "BOT."
Has Botanix Pharmaceuticals been receiving favorable news coverage?
Media stories about BOT stock have trended extremely negative on Friday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Botanix Pharmaceuticals earned a coverage optimism score of -4.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. View News Stories for Botanix Pharmaceuticals.
Who are some of Botanix Pharmaceuticals' key competitors?
Some companies that are related to Botanix Pharmaceuticals include Mesoblast (MSB), Neptune Wellness Solutions (NEPT), Oxford BioMedica (OXB), Kodiak Sciences (KOD), Starpharma (SPL), Resverlogix (RVX), BELLUS Health (BLU), Biotest (BIO), ProMetic Life Sciences (PLI), Theratechnologies (TH), Senesco Technologies (ELOX), Monash IVF Group (MVF), Emerald Health Therapeutics (EMH), Rafael (RFL) and Paradigm Biopharmaceuticals (PAR).
What other stocks do shareholders of Botanix Pharmaceuticals own?
Who are Botanix Pharmaceuticals' key executives?
Botanix Pharmaceuticals' management team includes the folowing people:
- Mr. Matthew Callahan, Founder & Exec. Director (Age 46)
- Dr. Michael Thurn Ph.D., COO & Exec. Director
- Dr. Henry William Bosch, Chief Scientific Officer & Exec. Director
- Dr. Stephane Levy, Chief Medical Officer
- Mr. Simon Robertson B.Bus, M Appl. Fin, CA, Company Sec.
What is Botanix Pharmaceuticals' stock price today?
One share of BOT stock can currently be purchased for approximately A$0.25.
How big of a company is Botanix Pharmaceuticals?
What is Botanix Pharmaceuticals' official website?
How can I contact Botanix Pharmaceuticals?
Botanix Pharmaceuticals' mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580.
MarketBeat Community Rating for Botanix Pharmaceuticals (ASX BOT)
MarketBeat's community ratings are surveys of what our community members think about Botanix Pharmaceuticals and other stocks. Vote "Outperform" if you believe BOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
